Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi‐quantitatively: steatosis (0‐3), lobular inflammation (0‐2), hepatocellular ballooning (0‐2), and fibrosis (0‐4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization (“NASH,” “borderline,” or “not NASH”) were evaluated by using weighted kappa statistics. Inter‐rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of ≥5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as “not NASH.” (HEPATOLOGY 2005;41:1313–1321.)

[1]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[2]  E. Roberts,et al.  Steatohepatitis in children. , 2002, Best practice & research. Clinical gastroenterology.

[3]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[4]  P. Bedossa,et al.  Observer variation in assessment of liver biopsies of alcoholic patients. , 1988, Alcoholism, clinical and experimental research.

[5]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[6]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[7]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[8]  J. Everhart,et al.  Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. , 2003, Gastroenterology.

[9]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[10]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[11]  E. Roberts,et al.  Nonalcoholic steatohepatitis in children , 2003, Current gastroenterology reports.

[12]  G. Farrell.  Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region? , 2003, Journal of gastroenterology and hepatology.

[13]  J. Goldblum,et al.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[14]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[15]  A. Sanyal,et al.  AGA technical review on nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[16]  C. Day,et al.  Non‐alcoholic steatohepatitis: Definitions and pathogenesis , 2002, Journal of gastroenterology and hepatology.

[17]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[18]  E. Brunt,et al.  Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond , 2000, Hepatology.

[19]  Nash Crn.  Nonalcoholic steatohepatitis clinical research network , 2003, Hepatology.

[20]  A. Reuben.  Child comes of age , 2002, Hepatology.

[21]  A. McCullough,et al.  Update on nonalcoholic fatty liver disease. , 2002, Journal of clinical gastroenterology.

[22]  A. Perez-Atayde,et al.  Idiopathic steatohepatitis in childhood: a multicenter retrospective study. , 1995, The Journal of pediatrics.

[23]  S. Locarnini.  Molecular virology of hepatitis B virus. , 2004, Seminars in liver disease.

[24]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.

[25]  P. Diggle.  Analysis of Longitudinal Data , 1995 .

[26]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[27]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.

[28]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[29]  Z. Younossi,et al.  Non‐alcoholic fatty liver disease: An overview , 2002, Journal of gastroenterology and hepatology.